Anti-Tnf Side Effects in the Treatment of Chronic InflammatoryBowel Disease

Authors

  • I Elhidaoui Service de Gastroentérologie CHU Mohammed VI Marrakech Author
  • S Oubaha Laboratoire de physiologie université CADDY AYYAD faculté de médecine et de pharmacie de Marrakech Author
  • K Benjouad Service de Gastroentérologie CHU Mohammed VI Marrakech Author
  • Z Samlani Service de Gastroentérologie CHU Mohammed VI Marrakech Author
  • K Krati Service de Gastroentérologie CHU Mohammed VI Marrakech Author

DOI:

https://doi.org/10.47363/JGHR/2021(2)110

Keywords:

Biological Therapy, Anti Tnf, Ibd, Ulcerative Colitis, Crohn’s Disease, Secondary Effects

Abstract

IBD is a common, serious and disabling chronic digestive disease, Their different manifestations, whether digestive and extra-digestive, require a multi-professional care adapted to each specific patient. Anti-TNFs are now an essential therapeutic weapon in the management of inflammatory bowel disease (IBD). Their effectiveness in both the short and long term has been demonstrated in various studies. However short and long term anti-tnf results vary from patient to patient which can be explained in many cases by the significant number of discontinued treatment in patients that experience side effects. The purpose of our work is to study the different side effects occurring in patients under biotherapy, the management of these side effects and their prevention. We prospectively analyzed since four years the medical records of 54 IBD patients who received anti-TNF
treatment. An exhaustive pre-therapeutic assessment was performed systematically in all patients. A clinical and biological control was carried out systematically before each therapeutic administration to search for undesirable reactions. Side effects were classified into several categories including immediate hypersensitivity reactions, dermatological complications, infectious, neurological, haematological, neoplasic and cardiac complications. During this period, 54 patients were treated with biotherapies, representing 24.2% of all IBD patients. We observed 29 side effects, an incidence of 46% including two severe effects 3.5%, occurring on average after one month of treatment. The hematological undesirable effects were the most frequent appearedin 14 patients (26%), severe infection specifically tuberculosis appeared in 2 patients (3.6%), allergic effects were severe in only one case (anaphylactic shock), finally the secondary cutaneous lesions of Anti-TNF were observed in a single patient (extensive psoriasis). Severe adverse reactions led to permanent
discontinuation of Anti-TNF in 24.1% of cases. The use of anti-TNF treatment is likely to generate numerous undesirable effects, hence the advantage of respecting the recommendations relating to the assessment before any treatment with biotherapy and of making regular clinical follow-up during treatment with a meticulous clinical examination as well as biological monitoring in order to prevent the occurrence of these complications, and to manage them correctly once they appear.

Author Biographies

  • I Elhidaoui, Service de Gastroentérologie CHU Mohammed VI Marrakech

    Service de Gastroentérologie CHU Mohammed VI Marrakech

  • S Oubaha, Laboratoire de physiologie université CADDY AYYAD faculté de médecine et de pharmacie de Marrakech


    Laboratoire de physiologie université CADDY AYYAD faculté de médecine et de pharmacie de Marrakech

  • K Benjouad, Service de Gastroentérologie CHU Mohammed VI Marrakech

    Service de Gastroentérologie CHU Mohammed VI Marrakech

  • Z Samlani, Service de Gastroentérologie CHU Mohammed VI Marrakech

    Service de Gastroentérologie CHU Mohammed VI Marrakech

  • K Krati, Service de Gastroentérologie CHU Mohammed VI Marrakech

    Service de Gastroentérologie CHU Mohammed VI Marrakech

Downloads

Published

2021-03-29